Research Site Accelerator

Research Catalyst operates a specialized clinical infrastructure designed to streamline the connection between research sites and specific patient populations. By focusing on highly specific, treatment-refractory conditions—including Dementia, Parkinson’s disease, and Tardive Dyskinesia—we provide the foundational data and access required to advance complex clinical programs. Our model focuses on removing the logistical bottlenecks that traditionally delay clinical trials.

FDA Approved Drug Launch

Delivering the strategic commercialization and medical affairs framework necessary to transition assets from clinical validation to market reality. By analyzing deep data sets—including over 870,000 longitudinal data points on patient symptoms and medication history—we help partners navigate the post-approval landscape. This capability ensures that new therapies are supported by a comprehensive understanding of patient needs, provider prescribing habits, and the overall commercial ecosystem.

Legal Advocates

Research Catalyst’s growth is characterized by our ability to build specialized solutions for the Parkinson’s community. This is best exemplified by our role in founding and supporting a dedicated legal services entity. Recognizing that patient care involves more than just clinical intervention, we utilized our organizational expertise to establish a separate, mission-aligned firm. This approach allows us to address the diverse needs of the ecosystem while maintaining a focus on high-impact, professional service delivery.

PD SaMD Developer

SaMD R&D & 2026 Frameworks Innovation at Research Catalyst extends into proprietary digital health solutions. We maintain a dedicated pipeline for Software as a Medical Device (SaMD), which has become financially viable under the 2026 Medicare Physician Fee Schedule. By utilizing new Remote Therapeutic Monitoring (RTM) codes and advanced Multimodal AI capabilities, we are now working towards integrating clinical-grade biometrics into predictive models for chronic disease management and proprietary therapeutic interventions.

A Legacy of Integration: Defining the New Standard in CNS Innovation

Research Catalyst was founded on the principle that solving complex neurological challenges requires more than just service delivery—it requires a unified infrastructure. Over the past decade, we have systematically moved upstream, evolving from a premier clinical site destination into a vertically integrated venture platform. This progression has allowed us to master every critical touchpoint in the therapeutic lifecycle, ensuring that innovation is never stalled by logistical or commercial fragmentation.

  • Foundational Infrastructure: Building and scaling high-performance research environments to establish a national standard for patient care and data integrity.

  • Strategic Medical Affairs: Moving beyond execution to lead international medical affairs, where we guide global protocols and regulatory pathways for major pharmaceutical partners.

  • Market Commercialization: Bridging the gap between clinical validation and patient access by implementing sophisticated launch strategies for high-value CNS therapies.

  • Venture Incubation: Identifying ecosystem gaps—from specialized legal support to digital diagnostics—and incubating purpose-built entities to capture unmet value.

Today, this vertical integration culminates in the realization of our long-standing vision for proprietary innovation. Supported by the maturation of the 2026 digital health reimbursement frameworks and advanced multimodal AI capabilities, we have resumed the development of PD Motion, our Software as a Medical Device (SaMD) initiative. By combining deep clinical insights with a proven infrastructure for asset development, we are closing the loop on a decades-long mission to provide comprehensive, technology-driven solutions for the Parkinson’s community.

Regulatory Architecture & Professional Integrity

Our platform is built on a foundation of strategic compliance and deep operational fluency within the healthcare legal landscape. We maintain a broad mastery of the regulatory environment—ranging from HIPAA-compliant digital infrastructure to the specialized integration of professional services. By navigating the intersection of HHS and FDA guidelines, we ensure that every initiative, including our spun-off entities like PD Law, operates within a methodology that prioritizes informed consent and institutional transparency. This mastery allows us to transform complex legal requirements into a strategic advantage, protecting the integrity of our assets and the trust of the patients we serve.

Ethical Innovation: A Decade of Digital Healthcare

The development of proprietary digital health tools is the culmination of a ten-year track record in tech-driven care. Our commitment to Software as a Medical Device (SaMD) is grounded in an ethical approach to innovation that spans over a decade of research, development, and patient engagement. This history of technical excellence enables us to lead the development of PD Motion, utilizing the latest advancements in Multimodal AI to bridge the gap between scientific promise and clinical reality. By prioritizing evidence-based therapeutic intent, we ensure that our digital interventions serve as reliable, clinician-supervised tools for chronic disease management.